Russians love Putin's dustup with the West. But they've stopped spending money
Why rival discounters are vying for control of Family Dollar Stores
Twitter's head of product, Daniel Graf, must make the service more user-friendly without offending hard-core fans
Yale's Robert Shiller is sending up warning flares. It may be best to ignore him
To minimize flood chaos, turn the hospital upside down
Bayer is marketing Berocca as performance drink, but Australians know what it's really for
After years of effort, top B-schools still enroll only about 40 percent female MBAs
Advice for a small bed-and-breakfast trying to get on the map for international tourists
Santa Clara, Calif.
Founders: Dr. Gerrit Klaerner, Dr. Scott Rocklage, Dr. Detlef Albrecht, and Dr. Jerry Buysse
VC Investment over the last four quarters: $33 million
In October 2007, Relypsa was spun out of Amgen (AMGN) by the founders of a previous biotech startup, Ilypsa, which the biotech company had acquired for $420 million earlier that year. The 47-employee company is developing treatments for hyperkalemia, a potentially deadly condition in patients with heart and kidney disease. By acting in the gastrointestinal tract only, Relypsa's drugs would reduce the risk of side effects that can occur with treatments that are absorbed into the bloodstream.
Key to startup success: "... Intense focus, speed, and efficient use of capital. We have been able to take our lead product program from the initial clinical testing stage in a Phase 1 trial [investigational new drug] to Phase 2 clinical development in nine months, something that most drug discovery and development startups typically achieve ... in three to four years."